Pramlintide Research Dosage: Published Protocol Reference
Pramlintide dosage references vary by route and study context. The database lists Subcutaneous injection: 60 mcg (Type 2) or 15-60 mcg (Type 1), Before each major meal. These are research-context references, not a universal protocol.
Direct Answer
Pramlintide (Symlin) is FDA-approved as an adjunct to insulin in both type 1 and type 2 diabetes, with multiple Phase 3 RCTs supporting meaningful HbA1c and postprandial glucose reduction. Its amylin-mimetic mechanism is distinct from GLP-1 agonism. In combination with GLP-1 agents, amylin agonism shows additive weight-loss effects. A well-validated compound with a real regulatory record.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Weight Loss & Metabolic
- Best for
- Insulin-adjunct glycemic control, postprandial glucose management, amylin pathway research
Research Dosage References
- <strong>Subcutaneous injection</strong> - 60 mcg (Type 2) or 15-60 mcg (Type 1) - Before each major meal - Type 2: Start at 60 mcg, may increase to 120 mcg. Type 1: Start at 15 mcg, titrate by 15 mcg increments to 30 or 60 mcg. Reduce mealtime insulin by 50% when initiating pramlintide.
Half-Life
~48 minutes.
Evidence Limits
Dosage entries are compiled from labels, published studies, and research-context references where available. For Pramlintide, the evidence grade is Level A, and the current research status is FDA Approved.
Safety Signals
- Boxed warning: Severe hypoglycemia risk, particularly in type 1 diabetes - always reduce mealtime insulin dose by 50% when initiating pramlintide
- Should not be used in patients with hypoglycemia unawareness
- Contraindicated in patients with gastroparesis
- Not a substitute for insulin
- Should not be mixed with insulin in the same syringe
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Postprandial Glucose Control (Level A), Body Weight (Level A), and Glucagon Suppression (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Pramlintide Research Dosage: Published Protocol Reference." Last reviewed 2026-04-04. https://examinepeptides.com/answers/pramlintide-research-dosage/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.